Key result
Second-generation drug-eluting stents significantly reduced target vessel revascularization compared with bare metal stents in STEMI patients, without increasing mortality, myocardial infarction, or stent thrombosis.
Why the study?
Do first and second generation drug-eluting stents improve safety and efficacy compared to bare metal stents in patients with STEMI?
Do first and second generation drug-eluting stents improve safety and efficacy compared to bare metal stents in patients with STEMI?
Answers are grounded in this paper and cite their sources.
This review provides an overview of the safety and efficacy of first and second-generation drug-eluting stents in patients with STEMI.
Primary percutaneous coronary intervention is the preferred reperfusion strategy for patients presenting with ST-segment elevation myocardial infarction (STEMI). First generation drug-eluting stents (DES), (sirolimus drug-eluting stents and paclitaxel drug-eluting stents), reduce the risk of restenosis and target vessel revascularization compared to bare metal stents. However, stent thrombosis emerged as a major safety concern with first generation DES. In response to these safety issues, second generation DES were developed with different drugs, improved stent platforms and more biocompatible durable or bioabsorbable polymeric coating. This article presents an overview of safety and efficacy of the first and second generation DES in STEMI.
No takes yet. Share an insight, caveat, or question.
S Otsuki (2014) conducted a review in ST-segment elevation myocardial infarction (STEMI). Drug-eluting stents (DES) vs. Bare metal stents (BMS) was evaluated. Second-generation drug-eluting stents significantly reduced target vessel revascularization compared with bare metal stents in STEMI patients, without increasing mortality, myocardial infarction, or stent thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: